Skip to main content

Advertisement

SpringerLink
Log in

Association study of S100A9 gene polymorphisms with Parkinson's disease risk and age of disease onset

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Purpose

Intestinal inflammation is associated with several neurodegenerative diseases, including Parkinson's disease (PD). Intestinal inflammation is also closely related to genetic and environmental factors. S100 calcium-binding protein A9 (S100A9) is also thought to be genetically associated with intestinal inflammation and PD risk. This study investigated the association between S100A9 gene polymorphisms and PD risk and age of disease onset.

Methods

This study used a case–control method and included 242 PD patients and 242 healthy participants. Polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) was performed. S100A9 expression in the serum of the patients and controls was detected using reverse transcription‑quantitative PCR (RT-qPCR).

Results

The CC genotype and C allele of the rs3014866 polymorphism in S100A9 had significantly higher distribution in PD patients. The recessive and dominant models demonstrated that the patients carrying the rs3014866 C allele had a significantly increased risk of developing PD as compared with patients homozygous for the TT genotype. The generalized linear model results demonstrated that rs3014866 was associated with the age of disease onset independent of environmental exposure factors (smoking and toxins). Furthermore, the S100A9 mRNA transcription level in the patients’ serum was significantly higher than that of the controls. Moreover, the serum of patients with the CC genotype had higher S100A9 expression levels.

Conclusions

The results combined the relationship between S100A9 and PD susceptibility and age of disease onset. The findings might suggest new ideas for PD clinical diagnosis and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and material

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Code availability

Not applicable.

References

  1. Tolosa E, Garrido A, Scholz SW et al (2021) Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 20(5):385–397. https://doi.org/10.1016/S1474-4422(21)00030-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. De Miranda BR, Goldman SM, Miller GW et al (2022) Preventing Parkinson’s disease: an environmental agenda. J Parkinsons Dis 12(1):45–68. https://doi.org/10.3233/JPD-212922

    Article  PubMed  PubMed Central  Google Scholar 

  3. Powell A, Matar E, Lewis SJG (2022) Treating hallucinations in Parkinson’s disease. Expert Rev Neurother 22(6):455–468. https://doi.org/10.1080/14737175.2021.1851198

    Article  CAS  PubMed  Google Scholar 

  4. Qi S, Yin P, Wang L et al (2021) Prevalence of Parkinson’s disease: a community-based study in China. Mov Disord 36(12):2940–2944. https://doi.org/10.1002/mds.28762

    Article  PubMed  Google Scholar 

  5. Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384–386. https://doi.org/10.1212/01.wnl.0000247740.47667.03

    Article  CAS  PubMed  Google Scholar 

  6. Romano S, Savva GM, Bedarf JR et al (2021) Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis 7(1):27. https://doi.org/10.1038/s41531-021-00156-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cryan JF, O’Riordan KJ, Sandhu K et al (2020) The gut microbiome in neurological disorders. Lancet Neurol 19(2):179–194. https://doi.org/10.1016/S1474-4422(19)30356-4

    Article  CAS  PubMed  Google Scholar 

  8. Gordon J, Lockard G, Monsour M (2022) Sequestration of inflammation in Parkinson’s disease via stem cell therapy. Int J Mol Sci. https://doi.org/10.3390/ijms231710138

    Article  PubMed  PubMed Central  Google Scholar 

  9. Nacken W, Roth J, Sorg C et al (2003) S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 60(6):569–580. https://doi.org/10.1002/jemt.10299

    Article  CAS  PubMed  Google Scholar 

  10. Chen Y, Ouyang Y, Li Z et al (2023) S100A8 and S100A9 in Cancer. Biochim Biophys Acta 1878(3):188891. https://doi.org/10.1016/j.bbcan.2023.188891

    Article  CAS  Google Scholar 

  11. Dea-Ayuela MA, Rama-Iñiguez S, Bolás-Fernandez F (2008) Enhanced susceptibility to Trichuris muris infection of B10Br mice treated with the probiotic Lactobacillus casei. Int Immunopharmacol 8(1):28–35. https://doi.org/10.1016/j.intimp.2007.10.003

    Article  CAS  PubMed  Google Scholar 

  12. Horvath I, Jia X, Johansson P et al (2016) Pro-inflammatory S100A9 Protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer’s disease. ACS Chem Neurosci 7(1):34–39. https://doi.org/10.1021/acschemneuro.5b00265

    Article  CAS  PubMed  Google Scholar 

  13. Kim HJ, Chang KA, Ha TY et al (2014) S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model. PLoS ONE 9(2):e88924. https://doi.org/10.1371/journal.pone.0088924

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397(10291):2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X

    Article  CAS  PubMed  Google Scholar 

  15. Abitew AM, Sobti RC, Sharma VL et al (2020) Analysis of transporter associated with antigen presentation (TAP) genes polymorphisms with HIV-1 infection. Mol Cell Biochem 464(1–2):65–71. https://doi.org/10.1007/s11010-019-03649-x

    Article  CAS  PubMed  Google Scholar 

  16. Lubomski M, Tan AH, Lim SY et al (2020) Parkinson’s disease and the gastrointestinal microbiome. J Neurol 267(9):2507–2523. https://doi.org/10.1007/s00415-019-09320-1

    Article  PubMed  Google Scholar 

  17. Dănău A, Dumitrescu L, Lefter A et al (2021) Small intestinal bacterial overgrowth as potential therapeutic target in Parkinson’s disease. Int J Mol Sci. https://doi.org/10.3390/ijms222111663

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lee HS, Lobbestael E, Vermeire S et al (2021) Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links. Gut 70(2):408–417. https://doi.org/10.1136/gutjnl-2020-322429

    Article  CAS  PubMed  Google Scholar 

  19. Williams GP, Schonhoff AM, Jurkuvenaite A et al (2021) CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson’s disease. Brain 144(7):2047–2059. https://doi.org/10.1093/brain/awab103

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gorecki AM, Bakeberg MC, Theunissen F et al (2020) Single nucleotide polymorphisms associated with gut homeostasis influence risk and age-at-onset of Parkinson’s disease. Front Aging Neurosci 12:603849. https://doi.org/10.3389/fnagi.2020.603849

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wang C, Iashchishyn IA, Kara J et al (2019) Proinflammatory and amyloidogenic S100A9 induced by traumatic brain injury in mouse model. Neurosci Lett 699:199–205. https://doi.org/10.1016/j.neulet.2019.02.012

    Article  CAS  PubMed  Google Scholar 

  22. Chen L, Chen X, Wang Y et al (2022) Polymorphisms of calgranulin genes and ischemic stroke in a Chinese population. J Inflamm Res 15:3355–3368. https://doi.org/10.2147/JIR.S360775

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ortega FJ, Mercader JM, Moreno-Navarrete JM et al (2013) Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. J Mol Med (Berl) 91(4):523–534. https://doi.org/10.1007/s00109-012-0979-8

    Article  CAS  PubMed  Google Scholar 

  24. Wang W, Zhou J, Chen M et al (2018) Exposure to concentrated ambient PM(2.5) alters the composition of gut microbiota in a murine model. Part Fibre Toxicol 15(1):17. https://doi.org/10.1186/s12989-018-0252-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kowalski K, Mulak A (2019) Brain-gut-microbiota axis in Alzheimer’s disease. J Neurogastroenterol Motil 25(1):48–60. https://doi.org/10.5056/jnm18087

    Article  PubMed  PubMed Central  Google Scholar 

  26. Socała K, Doboszewska U, Szopa A et al (2021) The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res 172:105840. https://doi.org/10.1016/j.phrs.2021.105840

    Article  CAS  PubMed  Google Scholar 

  27. Wang C, Iashchishyn IA, Pansieri J et al (2018) S100A9-driven amyloid-neuroinflammatory cascade in traumatic brain injury as a precursor state for Alzheimer’s disease. Sci Rep 8(1):12836. https://doi.org/10.1038/s41598-018-31141-x

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  28. Qiu X, Ping S, Kyle M et al (2020) S100 calcium-binding protein A9 knockout contributes to neuroprotection and functional improvement after traumatic brain injury. J Neurotrauma 37(7):950–965. https://doi.org/10.1089/neu.2018.6170

    Article  PubMed  Google Scholar 

  29. Zhu S, Wang J, Zhang Y et al (2017) The role of neuroinflammation and amyloid in cognitive impairment in an APP/PS1 transgenic mouse model of Alzheimer’s disease. CNS Neurosci Ther 23(4):310–320. https://doi.org/10.1111/cns.12677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by the Natural Science Foundation of Xiamen (2022FCX012503010463), the Medical and Health Guidance Project of Xiamen (3502Z20224ZD1136).

Author information

Author notes

  1. Xingqiong Wang and Hanxuan Liu equally contributed.

Authors and Affiliations

  1. School of Statistics, Renmin University of China, Beijing, 100000, China

    Xingqiong Wang & Jian Li

  2. Beijing Jinghua Anliang Technology Co., Ltd, Beijing, 100000, China

    Hanxuan Liu

  3. Clinical Biological Sample Center, Medical Innovation Research Division of Chinese, PLA General Hospital, Beijing, 100000, China

    Jingjing Jiang

  4. Department of Pain Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tinghua University, Beijing, 100000, China

    Teng Li

  5. Department of Pain Center, Xiamen Changgung Hospital, Xiamen, 361000, China

    Teng Li

Authors
  1. Xingqiong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanxuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingjing Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Teng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XW and TL conceived and designed the experiments and revised the manuscript. HL did genetic analyzes and collected the clinical data. XW, JL and JJ analyzed and interpreted the data; and drafted the manuscript. All authors were involved in the revision of the manuscript.

Corresponding author

Correspondence to Teng Li.

Ethics declarations

Conflict of interest

All authors report no declarations of interest.

Ethics approval

The study was designed and performed in agreement with the Declaration of Helsinki and was approved by Ethics Committee of The Xiamen Changgung Hospital (Approval number: XMCGIRB2022080). Written informed consent was obtained from individual or guardian participants.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Liu, H., Li, J. et al. Association study of S100A9 gene polymorphisms with Parkinson's disease risk and age of disease onset. Acta Neurol Belg (2024). https://doi.org/10.1007/s13760-024-02486-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13760-024-02486-0

Keywords

Search

Navigation